General
Preferred name
CAMOSTAT
Synonyms
Camostat mesylate ()
FOY-S980 ()
FOY305 ()
Camostat Mesilate ()
Camostat (mesylate) ()
FOY-305, FOY-S980 ()
Camostat methanesulfonate ()
Camostat-d6 (hydrochloride) ()
P&D ID
PD014283
CAS
59721-29-8
59721-28-7
2930627-60-2
Tags
available
covalent binder
drug
drug candidate
Drug indication
hemorrhage
Coronavirus Disease 2019 (COVID-19)
Middle East Respiratory Syndrome (MERS)
Severe acute respiratory syndrome (SARS)
Cystic fibrosis
COVID-19
Drug Status
approved
experimental
investigational
Max Phase
3.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Camostat mesylate (Camostat mesilate) is an orally active, synthetic serine protease inhibitor for chronic pancreatitis. Camostat mesylate, an inhibitor of TMPRSS2, shows antiviral activity against SARS-CoV-2. Camostat mesylate also inhibits the activity of prostasin, trypsin, and matriptase[1][2][3].
PRICE
35
DESCRIPTION
Publications and data are also linked to the camostat mesilate salt (PubChem CID 5284360). There is an active metabolite reported as FOY 251 but this also maps to the mesylate salt (PubChem CID 130394), with the parent compound being PubChem CID 130395
SARS-CoV-2 and COVID-19: Inhibition of TMPRSS2 partially blocks entry of SARS-CoV-2 into Caco-2 cells , a result which indicates an opportunity for repurposing this already approved drug for COVID-19. Complete blockade of SARS-CoV-2 entry can be achieved by combined inhibition of TMPRSS2 (by camostat) and the endosomal cysteine proteases cathepsins B and L (by ; E-64d). In August 2020 Edinburgh University, the CRUK's Centre for Drug Development and Latus Therapeutics began the Phase 2/3 SPIKE-1 trial (NCT04455815) of camostat in non-hospitalised CoV-2 positive patients, to determine if the drug can reduce the progression of COVID-19 symptoms- access CRUK's trial webpage here. (GtoPdb)
SARS-CoV-2 and COVID-19: Inhibition of TMPRSS2 partially blocks entry of SARS-CoV-2 into Caco-2 cells , a result which indicates an opportunity for repurposing this already approved drug for COVID-19. Complete blockade of SARS-CoV-2 entry can be achieved by combined inhibition of TMPRSS2 (by camostat) and the endosomal cysteine proteases cathepsins B and L (by ; E-64d). In August 2020 Edinburgh University, the CRUK's Centre for Drug Development and Latus Therapeutics began the Phase 2/3 SPIKE-1 trial (NCT04455815) of camostat in non-hospitalised CoV-2 positive patients, to determine if the drug can reduce the progression of COVID-19 symptoms- access CRUK's trial webpage here. (GtoPdb)
DESCRIPTION
Camostat is an orally active trypsin inhibitor. Camostat can reduce pancreatic fibrosis induced by repeated administration of superoxide dismutase inhibitors in rats, and decrease the proliferation and activation of pancreatic stellate cells (PSCs)[1].
DESCRIPTION
Potent GSK-3 inhibitor; also inhibits cdks
(Tocris Bioactive Compound Library)
DESCRIPTION
Orally active protease inhibitor
(Tocriscreen Plus)
DESCRIPTION
Camostat mesylate (FOY-S980) is a trypsin-like protease inhibitor and inhibits airway epithelial sodium channel (ENaC) function.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
3
Compound Sets
23
AdooQ Bioactive Compound Library
ChEMBL Drugs
CovalentInDB
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMatrix
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
Mcule NIBR MoA Box Subset
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
Tocriscreen Plus
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
57
Molecular Weight
398.16
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
3
Rotatable Bonds
7
Ring Count
2
Aromatic Ring Count
2
cLogP
1.39
TPSA
134.81
Fraction CSP3
0.2
Chiral centers
0.0
Largest ring
6.0
QED
0.28
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Enzymes
Target
epithelial sodium channel (ENaC)
SARS-CoV
Ser/Thr Protease
PRSS1
COVID-19,Sodium Channel
Primary Target
Other Proteases
MOA
Inhibitor
Known Trypsin inhibitor
Protease inhibitor
Member status
member
Indication
pancreatitis
Therapeutic Class
Antiviral Agents
Pathway
Cell Cycle/Checkpoint
Membrane Transporter/Ion Channel
Metabolism
Microbiology/virology
Anti-infection
Metabolic Enzyme/Protease
Source data
